# ETNA (NCT06078384)

> Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06078384
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: UNICANCER
- Conditions: Triple-negative Breast Cancer
- Interventions: Pembrolizumab 25 mg/ml; Paclitaxel injection
- Enrollment: 354
- Primary outcome: Distant disease-free survival (DDFS)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 4

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=etna-nct06078384